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successfully treated and not successfully treated with prescrip-
tion medication alone. Resource use included type and number
of physician visits, diagnostic tests, and type and number of OAB
complications, as well as monthly out-of-pocket expenses asso-
ciated with OAB, such as over the counter medications, co-pay-
ments for prescription medications, incontinence pads, and
laundry and dry cleaning. Statistical signiﬁcance was evaluated
at the a = 0.05 level. RESULTS: In total, 196 adults receiving
drug therapy for their OAB (mean age 63.4 years, 76% female)
responded to the survey, of whom 121 (62%) perceived them-
selves to be successfully treated. In general, respondents who
considered their OAB condition successfully treated tended to
consume signiﬁcantly fewer resources than respondents who
considered their OAB unsuccessfully treated, including: visits to
a primary care physician (0.9 vs 1.4, p < 0.01); urine tests (0.2
vs 0.5, p = 0.05); and pads used during the day (0.9 vs 1.9, p <
0.01); and experienced fewer urinary tract infections (0.3 vs 0.9,
p < 0.02). Median monthly out-of-pocket expenses for OAB
were $18 for successfully treated versus $30 for unsuccessfully
treated respondents (p < 0.05). CONCLUSIONS: Patients who
consider themselves successfully treated with OAB medications
consume fewer resources and incur fewer out-of-pocket
expenses. OAB drug therapies that increase patient perception of
treatment success could potentially lead to lower healthcare
resource consumption.
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OBJECTIVE: Reducing protein intake of patients with chronic
renal disease (CRD) signiﬁcantly reduces the number of patients
entering end-stage renal disease (ESRD). We conducted an eco-
nomic evaluation of dietary protein restriction on the progres-
sion of CRD. METHODS: We conducted a Cost-Beneﬁt Analysis
in the perspective of the Italian National Health Service (NHS)
based on data from Modiﬁcation in Diet in Renal Disease
(MDRD) Study. In the MDRD, patients with a glomerular ﬁl-
tration rates (GFR) of 25–55ml/min/1.73m2 were randomly
assigned to usual protein (1.3g/Kg/die) or low protein 
(0.58g/Kg/die) diet groups. It is expected that a patient would
receive a protein-restricted diet when his/her GFR falls under 
25ml/min/1.73m2 and to start dialysis when his/her GFR is 
5ml/min/1.73m2. We quantiﬁed cost of diet with aprotein
product (2000Kcal/die, 40gr/die of protein) and the assistance
of a nutritionist (once every two months) and cost of dialysis
using NHS tariffs. Data were applied to a 7 years time horizon.
We conducted a one-way sensitivity analysis varying costs and
beneﬁts by ± 10% and applied a 3% rate of discount. RESULTS:
Applying the mean decline of GFR obtained by the MDRD study
we estimated patients receiving a low protein intake to start dial-
ysis in 7 years. Patients with a usual protein diet would start dial-
ysis in 5 years. We estimated a cost of 6882€ for 7 years low
protein diet with aprotein products. This treatment would delay
by 2 years dialysis initiation with an estimated saving to the NHS
of 43,268€. We obtained a beneﬁt of 36,386€ per patient. These
results were robust in one-way sensitivity analyses. CONCLU-
SION: Using MDRD Study data, a low protein controlled diet,
in nephropatic patients, could delay the degeneration of
nephropathy extending the renal survival. This involves signi-
ﬁcative economic beneﬁts.
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OBJECTIVE: The objective of this project was to analyse the 1-
year direct medical costs of kidney transplantation performed in
Belgium. METHODS: Data from the last 150 patients who
received a kidney transplantation at UCL Cliniques Universi-
taires St Luc (Belgium) and for which a follow-up of 1-year was
available were analysed. All patients were adults at the age of
the transplantation and treated with cyclosporine. Patients ﬁles
were retrospectively analysed. Key parameters, such as: primary
hospitalisation for transplantation; immunosuppressive drug
use; patient survival; graft survival; acute rejection; CMV infec-
tion; other adverse events and serious complications; treatment
of adverse events; treatment of complications; repeat hospital-
ization; and follow-up hospital consultations were recorded.
Total length of stay in the hospital was also recorded. For each
patient, information up to 1-year post renal transplantation (or
until death if death occurred within 1-year of transplantation)
was collected. Costing information was obtained from anony-
mous hospital bills which provided amounts paid by the health
care payer and patient. Three perspectives were considered in
this study, i.e. the health care payer (INAMI/RIZIV), the patient,
and the societal perspectives. RESULTS: For the whole popula-
tion (n = 150), the mean direct medical costs from the societal
perspective, health care payer’s perspective, and patient’s per-
spective amounted to 40,574€, 38,566€ (of which 28,844€ for
hospitalisation only), and 2,008€, respectively. During this one
year period, patients were hospitalised for 29 days on average.
CONCLUSIONS: One year direct medical costs of kidney trans-
plantation are substantial. In Belgium, most of the direct medical
costs are borne by the health care payer, and the main cost driver
are hospital costs.
PUK7
WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY
PACKED RED BLOOD CELL TRANSFUSION (TR) IN
HEMODIALYSIS (HD) PATIENTS?
Kuehne FC1, Stoffel MP2, Barth C3, Baldamus CA4
1PharmacoConsult, Wanzleben, Germany; 2KfH, Cologne, Germany;
3KfH, Neu-Isenburg, Germany; 4University Cologne, Cologne,
Germany
OBJECTIVE: This analysis characterizes patients in need of high
EPO doses at still low Hb levels of below 10g/dl (poor EPO
response). Cost-effectiveness of TR in such cohort is assessed.
METHODS: A database (>9000pat.) was stratiﬁed by EPO
dosage and Hb level and analyzed according to several medical
outcome parameters. A cohort of pat with poor EPO response
was compared to patients with an EPO dosis of 2,500–10,600
(mean ± 1 SD) and a mean Hb level of 11.5g/dl. Costs and con-
sequences of EPO therapy and TR were analyzed for the cohort
of pat with poor EPO response. RESULTS: Patients (n = 233)
with poor EPO response (18,730U/week) showed a mean Hb
level of 9.0g/dl and a higher prevalence of cerebrovascular, liver,
and valvular heart disease and fewer days of hospital free sur-
vival time of 223 days compared to 273 days in the compara-
tive arm. The yearly costs of EPO therapy (15,660€) outweigh
the costs of transfusion therapy (5,250€) assuming 50 blood
units per year. CONCLUSION: Given the relatively sick popu-
lation with poor EPO response, the risks associated with TR such
as infections and iron overload is outbalanced. Since mortality
(historical group) and QoL (SF-36) data are available for these
groups, the cost-effectiveness (cost per QALY) will be calculated.
